ОКО ЯК ПРЕДИКТОР КАРДIОВАСКУЛЯРНОЇ ПАТОЛОГIЇ У ХВОРИХ НА ЦУКРОВИЙ ДIАБЕТ
DOI:
https://doi.org/10.21856/j-PEP.2011.2.12Ключові слова:
цукровий діабетАнотація
Глобальна розповсюдженiсть цукрового дiабету (ЦД) сягла 6,6 % (285 млн хворих) у 2010 р. i, як очiкується, складе 7,8 % (438 млн хворих) у 2030 р. Серед пацiєнтiв iз хворобами коронарних судин частота ЦД вища, нiж в популяцiї, а частота кардiоваскулярних хвороб вища у хворих на ЦД. В Cardiovascular Health Study, до якого були залученi особи вiком 65 рокiв i старшi, було визначено, що частота клiнiчної або субклiнiчної кардiоваскулярної хво- роби склала 70 % у осiб iз нормальними рiвнями глюкози, 77 % — у осiб iз пiдвищеного глюкозою натще i 86 % — у осiб iз вперше дiагностованим або верифiкованим ранiше ЦД
Посилання
IDF Diabetes Atlas, Fourth Edition, 2009.
Pyorala K. Diabetes and atherosclerosis: an epidemiologic view [Text] / K. Pyorala, M. Laakso, M. Uusitupa // Diabetes. Metab. Rev. — 1987. — Vol. 3 (2). — P. 463–524.
Libby P. Inflammation and atherosclerosis [Text] / P. Libby, P. M. Ridker, A. Maseri // Circulation. — 2002. — Vol. 105 (9). — P. 1135–1143.
Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorder [Text] / J. I. Barziay, C. F. Spiekerman, L. H. Kuller [et al.] // Diabetes Care. — 2001. — Vol. 24. — P. 1233–1239.
Moncada S. Nitric oxide: physiology, pathophysiology, and pharmacology [Text] / S. Moncada, R. M. Palmer, E. A. Higgs // Pharmacol. Rev. — 1991. — Vol. 43. — P. 109–142.
Shore A. Vascular biology and physiology. In a textbook of vascular medicine [Text] / A. Shore, J. Tooke, D. Lowe // Arnold. Bath. — 1996. — P. 7–42.
Vita J. A. Endothelial function: a barometer for cardiovascular risk? [Text] / J. A. Vita, J. F. Keaney // Circulation. — 2002. — Vol. 106. — P. 640–642.
Davignon J. Role of endothelial dysfunction in atherosclerosis [Text] / J. Davignon, P. Ganz // Circulation. — 2004. — Vol. 109. — Suppl. 1. — P. 27–32.
Deanfield J. E. Endothelial function and dysfunction: testing and clinical relevance [Text] / J. E. Deanfield, J. P. Halcox, T. J. Rabelink // Circulation. — 2007. — Vol. 115. — P. 1285–1295.
Sch¨achinger V. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease [Text] / V. Sch¨achinger, M. B. Britten, A. M. Zeiher // Circulation. — 2000. — Vol. 101. — P. 1899–1906.
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [Text] / J. A. Suwaidi, S. Hamasaki, S. T. Higano [et al.] // Circulation. — 2000. — Vol. 101. — P. 948–954.
Prognostic value of coronary vascular endothelial dysfunction [Text] / J. P. Halcox, W. H. Schenke, G. Zalos [et al.] // Circulation. — 2002. — Vol. 106. — P. 653–658.
Kannel W. B. Diabetes and cardiovascular disease: the Framingham Study [Text] / W. B. Kannel, D. L. McGee // JAMA. — 1979. — Vol. 241. — P. 2035–2038.
Hayden M. R. Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy [Text] / M. R. Hayden, S. C. Tyagi // Cardiovasc. Diabetol. — 2002. — P. 1–3.
Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women [Text] / D. S. Celermajer, K. E. Sorensen, D. J. Spiegelhater [et al.] // J. Am. Coll. Cardiol. — 1994. — Vol. 24. — P. 471–476.
Age-related reduction of NO availability and oxidative stress in humans [Text] / S. Taddei, A. Virdis, L. Ghiadoni [et al.] // Hypertension. — 2001. — Vol. 38. — P. 274–279.
Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent
dilation and upregulation of nuclear factor-kB [Text] / A. J. Donato, I. Eskurza, A. E. Silver [et al.] // Circ. Res. — 2007. — Vol. 100. — P. 1659–1666.
Tooke J. E. Microvascular functional abnormalities in diabetes: the role of the endothelium [Text] / J. E. Tooke, S. J. Morris, A. C. Shore // Diabetes. Res. Clin. Pract. — 1996. — Vol. 31. — P. S127 —S132.
Microcirculation in hypertension: a new target for treatment? [Text] / B. I. Levy, G. Ambrosio, A. R. Pries [et al.] // Circulation. — 2001. — Vol. 104. — P. 735–740.
Capillary recruitment is impaired in essential hypertension and relates to insulin’s metabolic and vascular actions [Text] / E. H. Serne, R. O. B. Gans, J. C. Maaten [et al.] // Cardiovasc. Res. — 2001. — Vol. 49. — P. 161–168.
Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome [Text] / E. H. Serne, R. T. de Jongh, E. C. Eringa [et al.] // Hypertension. — 2007. — Vol. 50. — P. 204–211.
Seals D. R. Stiffening our resolve against adult weight gain [Text] / D. R. Seals, P. E. Gates // Hypertension. — 2005. — Vol. 45. — P. 175–177.
Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance [Text] / R. T. de Jongh, E. H. Serne, R. G. IJzerman [et al.] // Circulation. — 2004b. — Vol. 109. — P. 2529–2535.
Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy [Text] / R. T. de Jongh, E. H. Serne, R. G. IJzerman [et al.] // Diabetes. — 2004a. — Vol. 53. — P. 2873–2882.
Visceral and truncal subcutaneous adipose tissue are associated with impaired capillary recruitment in healthy individuals [Text] / R. T. de Jongh E. H. Serne, R. G. Ijzerman [et al.] // J. Clin. Endocrinol. Metab. — 2006. — Vol. 91. — P. 5100–5106.
Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and noninsulin-dependent
diabetic subjects [Text] / H. Miettinen, S. M. Haffner, S. Lehto [et al.] // Stroke. — 1996. — Vol. 27. — P. 2033–2039.
Retinopathy and risk of congestive heart failure [Text] / T. Y. Wong, W. Rosamond, P. P. Chang [et al.] // JAMA. — 2005. — Vol. 293. —P. 63–69.
The Framingham Heart Study and the Framingham Eye Study. Diabetic retinopathy and cardiovascular disease in type II diabetics [Text] / R. Hiller, R. D. Sperduto, M. J. Podgor [et al.] // Am. J. Epidemiol. — 1988. — Vol. 128. — P. 402–409.
Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes [Text] / E. Faglia, F. Favales, P. Calia [et al.] // Diabetes Care. — 2002. — Vol. 25. — P. 2032–2036.
Association of ocular disease and mortality in a diabetic population [Text] / R. Klein, B. E. Klein, S. E. Moss [et al.] // Arch Ophtalmol. — 1999. — Vol. 117. — P. 1487–1495.
Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study [Text] / N. Cheung, J. J. Wang, R. Klein [et al.] // Diabetes Care. — 2007. — Vol. 30. — P. 1742–1746.
Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors [Text] / G. A. Nichols, T. A. Hillier, J. R. Erbey [et al.] // Diabetes Care. — 2001. — Vol. 24. — P. 1614–1619.
Bell D. S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes [Text] / D. S. Bell // Diabetes Care. — 2003. — Vol. 26. — P. 2433–2441.
Heart failure prevalence, incidence, and mortality in the elderly with diabetes [Text] / A. G. Bertoni, W. G. Hundley, M.W. Massing [et al.] // Diabetes Care. — 2004. — Vol. 27. — P. 699–703.
Galderisi M. Diastolic dysfunction and diabetic cardiomiopathy: evaluation by Doppler echocardiography [Text] / M. Galderisi // J. Am. Coll. Cardiol. — 2006. — Vol. 48. — P. 1548–1551.
Boundina S. Diabetic cardiomyopathy revisited [Text] / S. Boundina, E. D. Abel // Circulation. — 2007. — Vol. 115. — P. 3213–3223.
Factor S. M. Capillary microaneurysms in the human diabetic heart [Text] / S. M. Factor, E. M. Okun, T. Minase // N. Engl. J. Med. — 1980. — Vol. 302. — P. 384–388.
Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus [Text] / T. Akasaka, K. Yoshida, T. Hozumi [et al.] // J. Am. Coll. Cardiol. — 1997. — Vol. 30. — P. 935–941.
Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes [Text] / M. F. Di Carli, J. Janisse, G. Grunberger [et al.] // J. Am. Coll. Cardiol. — 2003. — Vol. 41. — P. 1387–1393.
Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels [Text] / H. Miura, R. E. Wachtel, F. R. Loberiza [et al.] // Circ. Res. — 2003. — Vol. 92. — P. 151–158.
Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy
after replenishment of local vascular endothelial growth factor [Text] / Y. S. Yoon, S. Uchida, O. Masuo [et al.] // Circulation. — 2005. — Vol. 111. — P. 2073–2085.
Kannel W. B. Role of diabetes in congestive heart failure: the Framingham study [Text] / W. B. Kannel, M. Hjortland, W. P. Castelli // Am. J. Cardiol. — 1974. — Vol. 34. — P. 29–34.
Schaffer W. B. Development of a cardiomyopathy in a middle of noninsulin-dependent diabetes [Text] / S.W. Schaffer, B. H. Tan, G. L. Wilson // Am. J. Physiol. — 1985. — Vol. 248. — P. 179–185.
Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women [Text] / A. Juutilainen, S. Lehto, T. Ronnemaa [et al.] // Diabetes Care. — 2007. — Vol. 30. — P. 292–299.
Diabetic retinopathy and risk of heart failure [Text] / N. Cheung, J. J. Wang, S. L. Rogers [et al.] // J Am Coll Cardiol. — 2008. — Vol. 51. — P. 1573–1578.
Moreno P. R. New aspects in the pathogenesis of diabetic atherothrombosis [Text] / P. R. Moreno, V. Fuster // J. Am. Coll. Cardiol. — 2004. — Vol. 44. — P. 2293–2300.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [Text] // N. Engl. J. Med. — 1993. — Vol. 329. — P. 977–986.
The Diabetes Control and Complications Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial [Text] // Kidney Int. — 1995. — Vol. 47. — P. 1703–1720.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [Text] // Lancet. — 1998. —
Vol. 352. — P. 837–853.
UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis [Text] / I. M. Stratton, E. M. Kohner, S. J. Aldington [et al.] // Diabetologia. — 2001. — Vol. 44. — P. 156 –163.
10-Year follow-up of intensive glucose control in type 2 diabetes [Text] / R. R. Holman, S. K. Paul, M. A. Bethel [et al.] // N. Engl. J. Med. — 2008. — Vol. 359. — P. 1577–1589.
Diabetes Control and Complications Trial (DCCT) / Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes among adolescents: outcomes after the conclusion of
the Diabetes Control and Complications Trial (DCCT) [Text] / N. H. White, P. A. Cleary, W. Dahms [et al.] // J. Pediatr. — 2001. —
Vol. 139. — P. 804–812.
Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents [Text] / N. H. White, W. Sun, P. A. Cleary [et al.] // Diabetes.– 2010. — Vol. 59. — P. 1244–1253.
Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial [Text] // J. Pediatr. — 1994. — Vol. 125. — P. 177–188
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group [Text] // N. Engl.
J. Med. — 2000. — Vol. 342. — P. 381–389.
Mattila T. K. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus [Text] / T. K. Mattila, A. de Boer // Drugs. — 2010. — Vol. 70 (17). — P. 2229–2245.
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [Text] / F. Ismail-Beigi, T. Craven, M. A. Banerji [et al.] // Lancet. — 2010. — Vol. 376. — P. 419–430.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [Text] / D. M. Nathan, P. A. Cleary, J. Y. Backlund [et al.] // N. Engl. J. Med. — 2005. — Vol. 353. — P. 2643–2653.
Leahy J. L. Does early use of insulin reduce complications of diabetes? [Text] / J. L. Leahy // International Forum for the Advancement of Diabetes Research and Care: Abstract book. — 29–30 April (Greece). — 2011. — P. 16–17.
Intensive glucose control and macrovascular outcomes in type 2 diabetes [Text] / F. M. Turnbull, C. Abraira, R. J. Andersen [et al.] // Diabetologia. — 2009. — Vol. 52, № 11. — P. 2288–2298.
Biomedical risk factors for decreased cognitive unctioning in type 1 diabetes: an 18 year followup of the Diabetes Control and Complications Trial (DCCT) cohort [Text] / A. M. Jacobson, C. M. Ryan, P. A. Cleary [et al.] // Diabetologia. — 2011. —
Vol. 54. — P. 245–255.
Banerji M. A. Efficacy and goal attainment with insulin glargine vs comparators [Text] / M. A. Banerji, M. Baron, L. Blonde // Diabetologia. — 2010. — Vol. 53. — P. S389.
A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-na¨ıve people with type 2 diabetes [Text] / J. Rosenstock, M. Davies, P. D. Home [et al.] // Diabetologia. — 2008. — Vol. 51. — P. 408–416.
Statement by an American Association of Clinical Endocrinologists / American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [Text] / H.W. Rodbard, P. S. Jellinger, J. A. Davidson [et al.] // Endocr. Pract. — 2009. — Vol. 15, № 6. – P. 540–559.
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long term, randomised, open-label study [Text] / J. Rosenstock, V. Fonseca, J. B. McGill [et al.]
// Diabetologia. — 2009. — Vol. 52. — P. 1778–1788.
Древаль А. В. Лечение сахарного диабета и сопутствующих заболеваний [Текст] / А. В. Древаль // М.: Эксмо — 2010. — 352 с.
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus [Text] / R. A. Whitmer, A. J. Karter, K. Yaffe [et al.] // JAMA. — 2009. — Vol. 301, № 15. — P. 1565–1572.
Insulin as an antiinflammatory and antiatherogenic modulator [Text] / P. Dandona, A. Chaudruhi, H. Ghanim, P. Mohanty // J. Am. Coll. Cardiol. — 2009. — Vol. 53 (Suppl. 5). — P. S14–20.
Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy [Text] / L. Monnier, C. Colette, E. Mas [et al.] // Diabetologia. — 2010. — Vol. 53, № 3. — P. 562–571.
Garg S. K. New insights into fasting blood glucose and glycemic variability [Text] / S. K. Garg // International Forum for the Advancement of Diabetes Research and Care: Abstract book. — 29–30 April (Greece). — 2011. — P. 10–11.
The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up [Text] / T. Takao, T. Ide, H. Yanagisava [et al.] // Diabetes Res. Clin. Pract. — 2010. — Vol. 89 (3). — P. 296–302.
IDF Diabetes Atlas, Second Edition, 2003.
ISSN 
ISSN 
